Analysis of flavonoid-based pharmacophores that inhibit aggrecanases (ADAMTS-4 and ADAMTS-5) and matrix metalloproteinases through the use of topologically constrained peptide substrates

Chemical Biology and Drug Design

Volumn 74, Issue 5, 2009, Pages 473-482

  Cudic, Mare ^a   Burstein, Gayle D ^a,b   Fields, Gregg B ^c   Lauer Fields, Janelle ^c  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

( ) epigallocatechin gallate; A disintegrin and metalloproteinase with thrombospondin motif; ADAMTS; Flavonoid; Fluorescence resonance energy transfer substrate; Inhibitor; Matrix metalloproteinase; Metalloproteinase

Indexed keywords

AGGRECANASE; CATECHOL; DEOXYRHAPONTIN; EPICATECHIN GALLATE; EPIGALLOCATECHIN GALLATE; FLAVONOID; MATRIX METALLOPROTEINASE INHIBITOR; PICEATANNOL; PYROGALLOL; RESVERATROL; RHAPONTIN; STILLBENE; UNCLASSIFIED DRUG;

ARTICLE; DRUG INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; PRIORITY JOURNAL;

ADAM PROTEINS; AMINO ACID SEQUENCE; ANTIOXIDANTS; CATECHIN; ENZYME ACTIVATION; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; MATRIX METALLOPROTEINASES; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PEPTIDES; PROCOLLAGEN N-ENDOPEPTIDASE; STILBENES;

EID: 70349742566     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2009.00885.x     Document Type: Article

References (44)

1. Vankemmelbeke M.N., Jones G.C., Fowles C., Ilic M.Z., Handley C.J., Day A.J., Knight C.G., Mort J.S., Buttle D.J. (2003) Selective inhibition of ADAMTS-1, -4 and -5 by catechin gallate esters. Eur J Biochem 270 : 2394 2403.
2. Garbisa S., Biggin S., Cavallarin N., Sartor L., Benelli R., Albini A. (1999) Tumor invasion: molecular shears blunted by green tea. Nat Med 5 : 1216.
3. Demeule M., Brossard M., Pagé M., Gingras D., Béliveau R. (2000) Matrix metalloproteinase inhibition by green tea catchins. Biochim Biophys Acta 1478 : 51 60.
4. Garbisa S., Sartor L., Biggin S., Salvato B., Benelli R., Albini A. (2001) Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate. Cancer 91 : 822 832.
5. Oku N., Matsukawa M., Yamakawa S., Asai T., Yahara S., Hashimoto F. et al. (2003) Inhibitory effect of green tea polyphenols on membrane-type 1 matrix metalloproteinase, MT1-MMP. Biol Pharm Bull 26 : 1235 1238.
6. Yamakawa S., Asai T., Uchida T., Matsukawa M., Akizawa T., Oku N. (2004) (-)-Epigallocatechin gallate inhibits membrane-type 1 matrix metalloproteinase, MT1-MMP, and tumor angiogenesis. Cancer Lett 210 : 47 55.
7. Ende C., Gebhardt R. (2004) Inhibition of matrix metalloproteinase-2 and -9 activities by selected flavonoids. Planta Med 70 : 1006 1008.
8. Lim H., Kim H.P. (2007) Inhibition of mammalian collagenase, matrix metalloproteinase-1, by naturally-occurring flavonoids. Planta Med 73 : 1267 1274.
9. Lauer-Fields J.L., Spicer T.P., Chase P.S., Cudic M., Burstein G.D., Nagase H. et al. (2008) Screening of potential ADAMTS-4 inhibitors utilizing a collagen-model FRET substrate. Anal Biochem 373 : 43 51.
10. Kimura Y., Sumiyoshi M., Baba K. (2008) Antitumor activities of synthetic and natural stilbenes through antiangiogenic action. Cancer Sci 99 : 2083 2096.
11. Cuccioloni M., Mozzicafreddo M., Bonfili L., Cecarini V., Eleuteri A.M., Angeletti M. (2009) Natural occuring polyphenols as template for drug design: focus on serine proteases. Chem Biol Drug Des 74 : 1 15.
12. Lauer-Fields J.L., Whitehead J.K., Li S., Hammer R.P., Brew K., Fields G.B. (2008) Selective modulation of matrix metalloproteinase 9 (MMP-9) functions via exosite inhibition. J Biol Chem 283 : 20087 20095.
13. Gooljarsingh L.T., Lakdawala A., Coppo F., Luo L., Fields G.B., Tummino P.J. et al. (2008) Characterization of an exosite binding inhibitor of matrix metalloprotease 13. Protein Sci 17 : 66 71.
14. Lauer-Fields J.L., Minond D., Chase P.S., Baillargeon P.E., Saldanha S.A., Stawikowska R. et al. (2009) High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem 17 : 990 1005.
15. Scheer J.M., Romanowski M.J., Wells J.A. (2006) A common allosteric site and mechanism in caspases. Proc Natl Acad Sci USA 103 : 7595 7600.
16. Dennis M.S., Eigenbrot C., Skelton N.J., Ultsch M.H., Santell L., Dwyer M.A. et al. (2000) Peptide exosite inhibitors of factor VIIa as anticoagulants. Nature 404 : 465 470.
17. Roberge M., Santell L., Dennis M.S., Eigenbrot C., Dwyer M.A., Lazarus R.A. (2001) A novel exosite on coagulation factor VIIa and its molecular interactions with a new class of peptide inhibitors. Biochemistry 40 : 9522 9531. (Pubitemid 32757890)
18. Izaguirre G., Rezale A.R., Olson S.T. (2008) Engineering functional antithrombin exosites in 1-proteinase inhibitor that specifically promote the inhibition of factor Xa and factor IXa. J Biol Chem 284 : 1550 1558.
19. Meltzer M., Hasenbein S., Hauske P., Kucz N., Merdanovic M., Grau S. et al. (2008) Allosteric activation of HtrA protease DegP by stress signals during bacterial protein quality control. Angew Chem Int Ed Eng 47 : 1332 1334.
20. Selent J., Kaleta J., Li Z., Lalmanach G., Brömme D. (2007) Selective inhibition of the collagenase activity of cathepsin K. J Biol Chem 282 : 16492 16501.
21. Lauer-Fields J.L., Sritharan T., Kashiwagi M., Nagase H., Fields G.B. (2007) Substrate conformation modulates aggrecanase (ADAMTS-4) affinity and sequence specificity: suggestion of a common topological specificity of functionally diverse proteases. J Biol Chem 282 : 142 150.
22. Fields C.G., Lovdahl C.M., Miles A.J., Matthias-Hagen V.L., Fields G.B. (1993) Solid-phase synthesis and stability of triple-helical peptides incorporating native collagen sequences. Biopolymers 33 : 1695 1707.
23. Hills R., Mazzarella R., Fok K., Liu M., Nemirovskiy O., Leone J. et al. (2007) Identification of an ADAMTS-4 cleavage motif using phase display leads to the development of fluorogenic peptide substrates and reveals matrillin-3 as a novel substrate. J Biol Chem 282 : 11101 11109.
24. Nagase H., Fields C.G., Fields G.B. (1994) Design and characterization of a fluorogenic substrate selectively hydrolyzed by stromelysin 1 (matrix metalloproteinase-3). J Biol Chem 269 : 20952 20957.
25. 2, a fluorogenic substrate with increased specificity constants for collagenases and tumor necrosis factor converting enzyme. Anal Biochem 328 : 166 173.
26. 1′ subsite identity on matrix metalloproteinase triple-helical peptidase activity and collagen specificity. J Biol Chem 281 : 38302 38313.
27. Lauer-Fields J.L., Broder T., Sritharan T., Nagase H., Fields G.B. (2001) Kinetic analysis of matrix metalloproteinase triple-helicase activity using fluorogenic substrates. Biochemistry 40 : 5795 5803.
28. Bhaskaran R., Palmier M.O., Lauer-Fields J.L., Fields G.B., Van Doren S.R. (2008) MMP-12 catalytic domain recognizes triple-helical peptide models of collagen V with exosites and high activity. J Biol Chem 283 : 21779 21788.
29. Kashiwagi M., Enghild J.J., Gendron C., Hughes C., Caterson B., Itoh Y. et al. (2004) Altered proteolytic activities of ADAMTS-4 expressed by C-terminal processing. J Biol Chem 279 : 10109 10119.
30. Gendron C., Kashiwagi M., Lim N.H., Enghild J.J., Thøgersen I.B., Hughes C. et al. (2007) Proteolytic activities of human ADAMTS-5: comparative studies with ADAMTS-4. J Biol Chem 282 : 18294 18306.
31. Kashiwagi M., Tortorella M., Nagase H., Brew K. (2001) TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem 276 : 12501 12504.
32. Wierzchacz C., Su E., Kolander J., Gebhardt R. (2009) Differential inhibition of matrix metalloproteinases-2, -9, and -13 activities by selected anthraquinones. Planta Med 75 : 327 329.
33. Saghatelian A., Jessani N., Joseph A., Humphrey M., Cravatt B.F. (2004) Activity-based probes for the proteomic profiling of metalloproteases. Proc Natl Acad Sci USA 101 : 10000 10005.
34. Zhang Y., Xu J., Levin J., Hegen M., Li G., Robertshaw H. et al. (2004) Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N- hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor - converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. J Pharmacol Exp Ther 309 : 348 355.
35. Wayne G.J., Deng S.-J., Amour A., Borman S., Matico R., Carter H.L. et al. (2007) TIMP-3 inhibition of ADAMTS-4 (aggrecanase-1) is modulated by interactions between aggrecan and the C-terminal domain of ADAMTS-4. J Biol Chem 282 : 20991 20998.
36. Shieh H.-S., Mathis K.J., Williams J.M., Hills R.L., Wiese J.F., Benson T.E. et al. (2008) High resolution crystal structure of the catalytic domain of ADAMTS-5 (aggrecanase-2). J Biol Chem 283 : 1501 1507.
37. Yeh L.-A., Chen J.M., Baculi F., Gingrich D.E., Shen T.Y. (1995) Inhibition of metalloproteinase by futoenone derivatives. Bioorg Med Chem Lett 5 : 1637 1642.
38. Barrantes E., Guinea M. (2003) Inhibition of collagenase and metallproteinases by aloins and aloe gel. Life Sci 72 : 843 850.
39. Gerhardt S., Hassall G., Hawtin P., McCall E., Flavell L., Minshull C. et al. (2007) Crystal structures of human ADAMTS-1 reveal a conserved catalytic domain and a disintegrin-like domain with a fold homologous to cysteine-rich domains. J Mol Biol 373 : 891 902.
40. Hajduk P.J., Greer J. (2007) A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 6 : 211 219.
41. Fattori D., Squarcia A., Bartoli S. (2008) Fragment-based approach to drug lead discovery: overview and advances in various techniques. Drugs R D 9 : 217 227.
42. Congreve M., Chessari G., Tisi D., Woodhead A.J. (2008) Recent developments in fragment-based drug discovery. J Med Chem 51 : 3661 3680.
43. Puerta D.T., Cohen S.M. (2004) A bioinorganic perspective on matrix metalloproteinase inhibition. Curr Topics Med Chem 4 : 1551 1573.
44. Hauske P., Ottmann C., Meltzer M., Ehrmann M., Kaiser M. (2008) Allosteric regulation of proteases. ChemBioChem 9 : 2920 2928.